Cargando…

Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort

AIM: To investigate the real‐world effectiveness of pharmacological treatments (buprenorphine, methadone) of opioid use disorder (OUD). DESIGN: A nation‐wide, register‐based cohort study. SETTING: Sweden. PARTICIPANTS: All residents aged 16–64 years living in Sweden using OUD medication from July 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Heikkinen, Milja, Taipale, Heidi, Tanskanen, Antti, Mittendorfer‐Rutz, Ellenor, Lähteenvuo, Markku, Tiihonen, Jari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305765/
https://www.ncbi.nlm.nih.gov/pubmed/35072314
http://dx.doi.org/10.1111/add.15814
_version_ 1784752398848229376
author Heikkinen, Milja
Taipale, Heidi
Tanskanen, Antti
Mittendorfer‐Rutz, Ellenor
Lähteenvuo, Markku
Tiihonen, Jari
author_facet Heikkinen, Milja
Taipale, Heidi
Tanskanen, Antti
Mittendorfer‐Rutz, Ellenor
Lähteenvuo, Markku
Tiihonen, Jari
author_sort Heikkinen, Milja
collection PubMed
description AIM: To investigate the real‐world effectiveness of pharmacological treatments (buprenorphine, methadone) of opioid use disorder (OUD). DESIGN: A nation‐wide, register‐based cohort study. SETTING: Sweden. PARTICIPANTS: All residents aged 16–64 years living in Sweden using OUD medication from July 2005 to December 2016 (n = 5757, 71.8% men) were identified from registers of prescriptions, inpatient and specialized outpatient care, causes of death, sickness absence and disability pensions. MEASUREMENTS: Main outcome: hospitalization due to OUD. Secondary outcomes: hospitalization due to any cause; death due to all, natural and external causes. Mortality was analyzed with between‐individual multivariate‐adjusted Cox hazards regression model. Recurrent outcomes, such as hospitalizations, were analyzed with within‐individual analyses to eliminate selection bias. OUD medication use versus non‐use was modelled with PRE2DUP (from prescription drug purchases to drug use periods) method. FINDINGS: Buprenorphine [hazard ratio (HR) = 0.73, 95% confidence interval (CI) = 0.54–0.97] and methadone (HR = 0.74, 95% CI = 0.59–0.93) use were associated with significantly lower risk of OUD hospitalization, but not any‐cause hospitalizations, compared with the time‐periods when the same individual did not use OUD medication. The use of buprenorphine and methadone were both associated with significantly lower risk of all‐cause mortality (HR = 0.45, 95% CI = 0.34–0.59; HR = 0.51, 95% CI = 0.41–0.63, respectively), compared with non‐use of both medications. Similar results were found for risk of mortality due to external causes (HR = 0.39; 95% CI = 0.27–0.54; HR = 0.40; 95% CI = 0.29–0.53, respectively), but not for mortality due to natural causes. The risk of OUD hospitalization and all‐cause mortality was decreased in all duration categories of studied medications (< 30, 31–180, 181–365 and >365 days), except for methadone use less than 30 days. CONCLUSIONS: The use of buprenorphine and methadone are both associated with a significantly lower risk of hospitalization due to opioid use disorder and death due to all and external causes, when compared with non‐use.
format Online
Article
Text
id pubmed-9305765
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93057652022-07-28 Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort Heikkinen, Milja Taipale, Heidi Tanskanen, Antti Mittendorfer‐Rutz, Ellenor Lähteenvuo, Markku Tiihonen, Jari Addiction Research Reports AIM: To investigate the real‐world effectiveness of pharmacological treatments (buprenorphine, methadone) of opioid use disorder (OUD). DESIGN: A nation‐wide, register‐based cohort study. SETTING: Sweden. PARTICIPANTS: All residents aged 16–64 years living in Sweden using OUD medication from July 2005 to December 2016 (n = 5757, 71.8% men) were identified from registers of prescriptions, inpatient and specialized outpatient care, causes of death, sickness absence and disability pensions. MEASUREMENTS: Main outcome: hospitalization due to OUD. Secondary outcomes: hospitalization due to any cause; death due to all, natural and external causes. Mortality was analyzed with between‐individual multivariate‐adjusted Cox hazards regression model. Recurrent outcomes, such as hospitalizations, were analyzed with within‐individual analyses to eliminate selection bias. OUD medication use versus non‐use was modelled with PRE2DUP (from prescription drug purchases to drug use periods) method. FINDINGS: Buprenorphine [hazard ratio (HR) = 0.73, 95% confidence interval (CI) = 0.54–0.97] and methadone (HR = 0.74, 95% CI = 0.59–0.93) use were associated with significantly lower risk of OUD hospitalization, but not any‐cause hospitalizations, compared with the time‐periods when the same individual did not use OUD medication. The use of buprenorphine and methadone were both associated with significantly lower risk of all‐cause mortality (HR = 0.45, 95% CI = 0.34–0.59; HR = 0.51, 95% CI = 0.41–0.63, respectively), compared with non‐use of both medications. Similar results were found for risk of mortality due to external causes (HR = 0.39; 95% CI = 0.27–0.54; HR = 0.40; 95% CI = 0.29–0.53, respectively), but not for mortality due to natural causes. The risk of OUD hospitalization and all‐cause mortality was decreased in all duration categories of studied medications (< 30, 31–180, 181–365 and >365 days), except for methadone use less than 30 days. CONCLUSIONS: The use of buprenorphine and methadone are both associated with a significantly lower risk of hospitalization due to opioid use disorder and death due to all and external causes, when compared with non‐use. John Wiley and Sons Inc. 2022-02-07 2022-06 /pmc/articles/PMC9305765/ /pubmed/35072314 http://dx.doi.org/10.1111/add.15814 Text en © 2022 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Reports
Heikkinen, Milja
Taipale, Heidi
Tanskanen, Antti
Mittendorfer‐Rutz, Ellenor
Lähteenvuo, Markku
Tiihonen, Jari
Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
title Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
title_full Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
title_fullStr Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
title_full_unstemmed Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
title_short Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
title_sort real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305765/
https://www.ncbi.nlm.nih.gov/pubmed/35072314
http://dx.doi.org/10.1111/add.15814
work_keys_str_mv AT heikkinenmilja realworldeffectivenessofpharmacologicaltreatmentsofopioidusedisorderinanationalcohort
AT taipaleheidi realworldeffectivenessofpharmacologicaltreatmentsofopioidusedisorderinanationalcohort
AT tanskanenantti realworldeffectivenessofpharmacologicaltreatmentsofopioidusedisorderinanationalcohort
AT mittendorferrutzellenor realworldeffectivenessofpharmacologicaltreatmentsofopioidusedisorderinanationalcohort
AT lahteenvuomarkku realworldeffectivenessofpharmacologicaltreatmentsofopioidusedisorderinanationalcohort
AT tiihonenjari realworldeffectivenessofpharmacologicaltreatmentsofopioidusedisorderinanationalcohort